Iran, Second Leading Country with Technical Knowledge of Radiopharmaceutical for Cancer Diagnosis

Tuesday, January 14, 2020 - 11:03

Iranian researchers from Institute for Nuclear Science and Technology of Atomic energy Organization of Iran have achieved to the technical knowledge of a kind of radiopharmaceutical for diagnosis of Lymphoma cancer.

According to an ISCA report, the research, supervised by Dr. Yavari, showed that researchers could successfully achieve to the knowledge of producing Tc-Rituximab, specific radiopharmaceutical that binds to the CD20 receptor which is highly expressed on the surface of B cells.

Tc-Rituximab can diagnose cancer markers, especially lymphoma cancer and as Khanjari, one of the researchers, said they could produce it and Rituximab as well.

Rituximab is a monoclonal antibody. It targets a protein called CD20 on the surface of the leukaemia and lymphoma cells. Rituximab sticks to all the CD20 proteins it finds. Then the cells of the immune system pick out the marked cells and kill them.

He noted that limit global access and its high production costs have been considered as the main reasons for Iranian scientists to produce Tc-Rituximab domestically.

Previously, Ali Akbar Salehi, director of the Atomic Energy Organization of Iran announced that Iran is exporting radiopharmaceuticals to 15 countries worldwide.

Iran is a pioneer in the field of developing and producing radiopharmaceuticals in western Asia, Salehi said, adding that the compounds are being exported to Egypt, India, Pakistan, Iraq, Lebanon, Syria, and some European countries.


Popular News

Latest News